Cargando…
Challenges of using external data in clinical trials- an illustration in patients with COVID-19
BACKGROUND: To improve the efficiency of clinical trials, leveraging external data on control and/or treatment effects, which is almost always available, appears to be a promising approach. METHODS: We used data from the experimental arm of the Covidicus trial evaluating high-dose dexamethasone in s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753019/ https://www.ncbi.nlm.nih.gov/pubmed/36522698 http://dx.doi.org/10.1186/s12874-022-01769-5 |
_version_ | 1784850872328519680 |
---|---|
author | Chevret, Sylvie Timsit, Jean-François Biard, Lucie |
author_facet | Chevret, Sylvie Timsit, Jean-François Biard, Lucie |
author_sort | Chevret, Sylvie |
collection | PubMed |
description | BACKGROUND: To improve the efficiency of clinical trials, leveraging external data on control and/or treatment effects, which is almost always available, appears to be a promising approach. METHODS: We used data from the experimental arm of the Covidicus trial evaluating high-dose dexamethasone in severely ill and mechanically ventilated COVID-19 patients, using published data from the Recovery trial as external data, to estimate the 28-day mortality rate. Primary approaches to deal with external data were applied. RESULTS: Estimates ranged from 0.241 ignoring the external data up to 0.294 using hierarchical Bayesian models. Some evidence of differences in mortality rates between the Covidicus and Recovery trials were observed, with an matched adjusted odds ratio of death in the Covidicus arm of 0.41 compared to the Recovery arm. CONCLUSIONS: These indirect comparisons appear sensitive to the method used. None of those approaches appear robust enough to overcome randomized clinical trial data. TRIAL REGISTRATION: Covidicus Trial: NCT04344730, First Posted: 14/04/2020; Recovery trial: NCT04381936 |
format | Online Article Text |
id | pubmed-9753019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97530192022-12-15 Challenges of using external data in clinical trials- an illustration in patients with COVID-19 Chevret, Sylvie Timsit, Jean-François Biard, Lucie BMC Med Res Methodol Research BACKGROUND: To improve the efficiency of clinical trials, leveraging external data on control and/or treatment effects, which is almost always available, appears to be a promising approach. METHODS: We used data from the experimental arm of the Covidicus trial evaluating high-dose dexamethasone in severely ill and mechanically ventilated COVID-19 patients, using published data from the Recovery trial as external data, to estimate the 28-day mortality rate. Primary approaches to deal with external data were applied. RESULTS: Estimates ranged from 0.241 ignoring the external data up to 0.294 using hierarchical Bayesian models. Some evidence of differences in mortality rates between the Covidicus and Recovery trials were observed, with an matched adjusted odds ratio of death in the Covidicus arm of 0.41 compared to the Recovery arm. CONCLUSIONS: These indirect comparisons appear sensitive to the method used. None of those approaches appear robust enough to overcome randomized clinical trial data. TRIAL REGISTRATION: Covidicus Trial: NCT04344730, First Posted: 14/04/2020; Recovery trial: NCT04381936 BioMed Central 2022-12-15 /pmc/articles/PMC9753019/ /pubmed/36522698 http://dx.doi.org/10.1186/s12874-022-01769-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chevret, Sylvie Timsit, Jean-François Biard, Lucie Challenges of using external data in clinical trials- an illustration in patients with COVID-19 |
title | Challenges of using external data in clinical trials- an illustration in patients with COVID-19 |
title_full | Challenges of using external data in clinical trials- an illustration in patients with COVID-19 |
title_fullStr | Challenges of using external data in clinical trials- an illustration in patients with COVID-19 |
title_full_unstemmed | Challenges of using external data in clinical trials- an illustration in patients with COVID-19 |
title_short | Challenges of using external data in clinical trials- an illustration in patients with COVID-19 |
title_sort | challenges of using external data in clinical trials- an illustration in patients with covid-19 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753019/ https://www.ncbi.nlm.nih.gov/pubmed/36522698 http://dx.doi.org/10.1186/s12874-022-01769-5 |
work_keys_str_mv | AT chevretsylvie challengesofusingexternaldatainclinicaltrialsanillustrationinpatientswithcovid19 AT timsitjeanfrancois challengesofusingexternaldatainclinicaltrialsanillustrationinpatientswithcovid19 AT biardlucie challengesofusingexternaldatainclinicaltrialsanillustrationinpatientswithcovid19 |